Prime Medicine (PRME) Enterprise Value (2021 - 2025)
Prime Medicine (PRME) has disclosed Enterprise Value for 5 consecutive years, with -$76.3 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Enterprise Value rose 37.94% year-over-year to -$76.3 million, compared with a TTM value of -$76.3 million through Sep 2025, up 37.94%, and an annual FY2024 reading of -$185.5 million, down 77.83% over the prior year.
- Enterprise Value was -$76.3 million for Q3 2025 at Prime Medicine, down from -$53.8 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$44.0 million in Q3 2023 and bottomed at -$253.7 million in Q4 2021.
- Average Enterprise Value over 5 years is -$131.0 million, with a median of -$120.6 million recorded in 2023.
- The sharpest move saw Enterprise Value surged 67.94% in 2023, then crashed 179.54% in 2024.
- Year by year, Enterprise Value stood at -$253.7 million in 2021, then rose by 26.03% to -$187.6 million in 2022, then soared by 44.41% to -$104.3 million in 2023, then crashed by 77.83% to -$185.5 million in 2024, then surged by 58.89% to -$76.3 million in 2025.
- Business Quant data shows Enterprise Value for PRME at -$76.3 million in Q3 2025, -$53.8 million in Q2 2025, and -$91.9 million in Q1 2025.